Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.80 +1.6%	$36.82	$23.42 ▼ $62.58	$2.25B	0.8	976,650 shs	722,567 shs
DNLI Denali Therapeutics	$15.49 +1.7%	$14.31	$10.57 ▼ $33.33	$2.26B	1.36	1.82 million shs	2.74 million shs
GLPG Galapagos	$32.00 +0.3%	$30.66	$22.36 ▼ $33.86	$2.11B	0.1	345,017 shs	161,129 shs
XNCR Xencor	$8.41 +13.0%	$8.34	$6.92 ▼ $27.24	$599.80M	0.89	719,850 shs	1.07 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+4.84%	-3.00%	+30.20%	-16.05%
DNLI Denali Therapeutics	0.00%	+5.37%	+13.31%	+15.42%	-37.46%
GLPG Galapagos	0.00%	-1.45%	-1.99%	+11.38%	+23.60%
XNCR Xencor	0.00%	+9.51%	-8.98%	+11.10%	-52.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3694 of 5 stars	3.4	2.0	4.3	2.9	0.8	1.9
DNLI Denali Therapeutics	4.2073 of 5 stars	3.6	1.0	4.7	3.1	3.3	0.0
GLPG Galapagos	0.1314 of 5 stars	0.7	2.0	0.0	0.6	0.0	0.6
XNCR Xencor	3.6847 of 5 stars	3.4	0.0	3.9	2.5	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	45.19% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	117.01% Upside
GLPG Galapagos	1.38	Strong Sell	$25.33	-20.83% Downside
XNCR Xencor	2.75	Moderate Buy	$23.71	181.98% Upside

Current Analyst Ratings Breakdown

Latest XNCR, AGIO, DNLI, and GLPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $15.00
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/7/2025	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $27.00
8/7/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$31.00 ➝ $26.00
8/5/2025	GLPG Galapagos	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Sell
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	61.76	N/A	N/A	$27.02 per share	1.44
DNLI Denali Therapeutics	$330.53M	6.85	N/A	N/A	$8.53 per share	1.82
GLPG Galapagos	$275.61M	7.65	$0.73 per share	44.07	$47.57 per share	0.67
XNCR Xencor	$110.49M	5.43	N/A	N/A	$9.63 per share	0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.53	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	10/22/2025 (Estimated)
XNCR Xencor	-$232.62M	-$2.40	N/A	N/A	N/A	-121.52%	-25.75%	-18.19%	11/5/2025 (Estimated)

Latest XNCR, AGIO, DNLI, and GLPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/6/2025	Q2 2025	XNCR Xencor	-$0.78	-$0.41	+$0.37	-$0.41	$22.59 million	$43.61 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
DNLI Denali Therapeutics	0.01	10.27	10.27
GLPG Galapagos	N/A	8.08	7.99
XNCR Xencor	N/A	5.34	5.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DNLI Denali Therapeutics	92.92%
GLPG Galapagos	32.46%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
DNLI Denali Therapeutics	12.50%
GLPG Galapagos	2.91%
XNCR Xencor	5.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.24 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
GLPG Galapagos	1,310	65.90 million	N/A	Optionable
XNCR Xencor	280	71.32 million	67.59 million	Optionable

XNCR, AGIO, DNLI, and GLPG Headlines

Recent News About These Companies

Xencor, Inc. (NASDAQ:XNCR) Receives $23.71 Consensus Target Price from Brokerages

3 hours ago | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by Analysts

August 24 at 2:42 AM | marketbeat.com

Aberdeen Group plc Grows Holdings in Xencor, Inc. $XNCR

August 23 at 4:34 AM | marketbeat.com

Royal Bank Of Canada Lowers Xencor (NASDAQ:XNCR) Price Target to $15.00

August 23 at 3:07 AM | americanbankingnews.com

Xencor, Inc. $XNCR Stock Holdings Lifted by Public Sector Pension Investment Board

August 22 at 3:48 AM | marketbeat.com

Xencor price target lowered to $15 from $32 at RBC Capital

August 21, 2025 | msn.com

Q3 Earnings Estimate for Xencor Issued By Leerink Partnrs

August 11, 2025 | marketbeat.com

Wedbush Estimates Xencor's Q3 Earnings (NASDAQ:XNCR)

August 11, 2025 | marketbeat.com

William Blair Analysts Boost Earnings Estimates for Xencor

August 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.37 EPS

August 10, 2025 | marketbeat.com

Xencor (XNCR) Receives a Buy from Leerink Partners

August 9, 2025 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

August 9, 2025 | finance.yahoo.com

Xencor (XNCR) Q2 Revenue Jumps 82%

August 9, 2025 | theglobeandmail.com

Xencor (NASDAQ:XNCR) Hits New 12-Month Low on Analyst Downgrade

August 8, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Wedbush Lowers Xencor (NASDAQ:XNCR) Price Target to $26.00

August 8, 2025 | marketbeat.com

Xencor price target lowered to $26 from $31 at Wedbush

August 8, 2025 | finance.yahoo.com

Primecap Management Co. CA Has $103.86 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

August 8, 2025 | marketbeat.com

XTX Topco Ltd Acquires 35,627 Shares of Xencor, Inc. (NASDAQ:XNCR)

August 7, 2025 | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) Short Interest Update

August 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR, AGIO, DNLI, and GLPG Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.80 +0.60 (+1.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$38.81 +0.01 (+0.02%)

As of 08/22/2025 05:51 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.49 +0.26 (+1.71%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.37 -0.12 (-0.77%)

As of 04:05 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Galapagos NASDAQ:GLPG

$32.00 +0.08 (+0.25%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$32.07 +0.07 (+0.21%)

As of 05:31 AM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Xencor NASDAQ:XNCR

$8.41 +0.97 (+13.04%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.49 +0.08 (+0.94%)

As of 04:27 AM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time